Dos Santos Rafael Guimarães, Bouso José Carlos, Rocha Juliana Mendes, Rossi Giordano Novak, Hallak Jaime E
Department of Neurosciences and Behavior, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil.
National Institute of Science and Technology - Translational Medicine, Ribeirão Preto, Brazil.
Risk Manag Healthc Policy. 2021 Mar 5;14:901-910. doi: 10.2147/RMHP.S300656. eCollection 2021.
Psychedelics or serotonergic hallucinogens are a group of substances that share the agonism of serotonergic 5-HT receptors as their main mechanism of action. Its main effects include changes in perception, cognitive process, and mood. Despite being used for centuries by different cultures in ritual contexts, these substances have currently aroused the interest of science and industry for their promising antidepressant, anxiolytic, and anti-addictive effects. Considering this evidence, this article aims to explore some of the possible health policy challenges to integrate these therapeutic tools into broad and heterogeneous health systems. As a main benefit, these substances produce rapid and enduring effects with the administration of single or few doses, which could lead to new treatment possibilities for patients with severe mental disorders resistant to the usual medications. The main challenge is associated with the fact that these substances remain scheduled in most countries and are associated with social stigma related to their recreational use (especially LSD and psilocybin). This situation makes it exceedingly difficult to conduct clinical trials, although international conventions allow such research. Ethically, this could be interpreted as a violation of human rights since thousands of people are prevented from having access to possible benefits. Interestingly, ritual ayahuasca use is more acceptable to the public than the use of psilocybin-containing mushrooms or LSD. The controlled, clinical use of LSD and psilocybin seems to be less criticized and is being explored by the industry. Rigorous scientific evidence coupled with industrial interests (LSD and psilocybin), together with respect for traditional uses (ayahuasca) and international conventions, seems to be the best way for these drugs to be integrated into health systems in the next years. Which highlights the need for an urgent dialogue between science, health system, society, and politics.
迷幻剂或血清素能致幻剂是一类物质,它们共同的主要作用机制是对血清素能5 - HT受体产生激动作用。其主要影响包括感知、认知过程和情绪的变化。尽管这些物质在不同文化的仪式背景中已被使用了几个世纪,但目前因其有前景的抗抑郁、抗焦虑和抗成瘾作用而引起了科学界和产业界的兴趣。考虑到这些证据,本文旨在探讨将这些治疗工具整合到广泛且多样的卫生系统中可能面临的一些卫生政策挑战。作为一个主要益处,这些物质在单次或少量给药时就能产生快速且持久的效果,这可能为对常规药物耐药的严重精神障碍患者带来新的治疗可能性。主要挑战在于,这些物质在大多数国家仍被列入管制清单,并且与它们用于娱乐用途(尤其是麦角酸二乙酰胺和裸盖菇素)所带来的社会污名相关。这种情况使得开展临床试验极其困难,尽管国际公约允许此类研究。从伦理上讲,这可能被解释为侵犯人权,因为成千上万的人被阻止获得可能的益处。有趣的是,公众对仪式性使用死藤水比使用含裸盖菇素的蘑菇或麦角酸二乙酰胺更为接受。麦角酸二乙酰胺和裸盖菇素的受控临床使用似乎受到的批评较少,并且正在被产业界探索。严格的科学证据加上产业利益(麦角酸二乙酰胺和裸盖菇素),再加上对传统用途(死藤水)的尊重以及国际公约,似乎是这些药物在未来几年融入卫生系统的最佳方式。这凸显了科学界、卫生系统、社会和政治之间迫切需要进行对话。